The Anti-angiogenic Potential of a Phellodendron amurense Hot Water Extract in Vitro and ex Vivo |
Kim, Eok-Cheon
(Division of Biological Science and Technology, Yonsei-Fraunhofer Medical Device Lab, College of Science and Technology, Yonsei University)
Kim, Seo Ho (Division of Biological Science and Technology, Yonsei-Fraunhofer Medical Device Lab, College of Science and Technology, Yonsei University) Bae, Kiho (Division of Biological Science and Technology, Yonsei-Fraunhofer Medical Device Lab, College of Science and Technology, Yonsei University) Kim, Han Sung (Department of Biomedical Engineering, Yonsei-Fraunhofer Medical Device Lab, College of Health Science, Yonsei University) Gelinsky, Michael (Center for Translational Bone, Joint and Soft Tissue Research, Medical Faculty and University Hospital, Technische Universitat Dreshden) Kim, Tack-Joong (Division of Biological Science and Technology, Yonsei-Fraunhofer Medical Device Lab, College of Science and Technology, Yonsei University) |
1 | Leu, C. H., Li, C. Y., Yao, X. and Wu, T. S. 2006. Constituents from the Leaves of Phellodendron amurense and Their Antioxidant Activity. Chem. Pharm. Bull. 54, 1308-1311. DOI |
2 | Kurebayashi, J., Otsuki, T., Kunisue, H., Mikami, Y., Tanaka, K., Yamamoto, S. and Sonoo, H. 1999. Expression of vascular endothelial growth factor (VEGF) family members in breast cancer. Jpn. J. Cancer Res. 90, 977-981. DOI |
3 | Lee, B. B., Sur, B. J., Shim, I. S., Lee, H. J. and Hahm, D. H. 2012. Phellodendron amurense and Its Major Alkaloid Compound, Berberine Ameliorates Scopolamine-Induced Neuronal Impairment and Memory Dysfunction in Rats. Kor. J. Physiol. Pharmacol. 16, 79-89. DOI |
4 | Lee, S. J., Park, K., Ha, S. D., Kim, W. J. and Moon, S. K. 2010. Gleditsia sinensis thorn extract inhibits human colon cancer cells: the role of ERK1/2, G2/M-phase cell cycle arrest and p53 expression. Phytother. Res. 24, 1870-1876. DOI |
5 | Lirdprapamongkol, K., Mahidol, C., Thongnest, S., Prawat, H., Ruchirawat, S., Srisomsap, C., Surarit, R., Punyarit, P. and Svasti, J. 2003. Anti-metastatic effects of aqueous extract of Helixanthera parasitica. J. Ethnopharmacol. 86, 253-256. DOI |
6 | Gong, J., Xie, J., Bedolla, R., Rivas, P., Chakravarthy, D., Freeman, J. W., Reddick, R., Kopetz, S., Peterson, A., Wang, H., Fischer, S. M. and Kumar, A. P. 2014. Combined targeting of STAT3/NF-κB/COX-2/EP4 for effective managementof pancreatic cancer. Clin. Cancer Res. 20, 1259-1273. DOI |
7 | Huang, S., Yang, N., Liu, Y., Hu, L., Zhao, J., Gao, J., Li, Y., Li, C., Zhang, X. and Huang, T. 2012. Grape seed proanthocyanidins inhibit angiogenesis via the downregulation of both vascular endothelial growth factor and angiopoietinsignaling. Nutr. Res. 32, 530-536. DOI |
8 | Visse, R. and Nagase, H. 2003. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ. Res. 92, 827-839. DOI |
9 | Xian, Y. F., Mao, Q. Q., Ip, S. P., Lin, Z. X. and Che, C. T. 2011. Comparison on the anti-inflammatory effect of Cortex Phellodendri Chinensis and Cortex PhellodendriAmurensis in 12-O-tetradecanoyl-phorbol-13-acetate-induced ear edema in mice. J. Ethnopharmacol. 137, 1425-1430. DOI |
10 | Xu, Y. and Ventura, S. 2010. Extracts of bark from the traditional Chinese herb Phellodendron amurense inhibit contractility of the isolated rat prostate gland. J. Ethnopharmacol. 127, 196-199. DOI |
11 | Zhou, H. Y., Wang, D. and Cui, Z. 2008. Ferulates, amurenlactone A and amurenamide A from traditional Chinese medicine cortex Phellodendri Amurensis. J. Asian Nat. Prod. Res. 10, 409-413. DOI |
12 | Zhang, L., Ji, Q., Liu, X., Chen, X., Chen, Z., Qiu, Y., Sun, J., Cai, J., Zhu, H. and Li, Q. 2013. Norcantharidin inhibits tumor angiogenesis via blocking VEGFR2/MEK/ERK signaling pathways. Cancer Sci. 104, 604-610. DOI |
13 | Yi, J. M., Park, J. S., Oh, S. M., Lee, J., Kim, J., Oh, D. S., Bang, O. S. and Kim, N. S. 2012. Ethanol extract of Gleditsia sinensis thorn suppresses angiogenesis in vitro and in vivo. BMC Complement. Altern. Med. 12, 243-252. DOI |
14 | Yoshiji, H., Kuriyama, S., Hicklin, D. J., Huber, J., Yoshii, J., Miyamoto, Y., Kawata, M., Ikenaka, Y., Nakatani, T., Tsujinoue, H. and Fukui, H. 1999. KDR/Flk-1 is a major regulator of vascular endothelial growth factorinduced tumor development and angiogenesis in murine hepatocellular carcinoma cells. Hepatology 30, 1179-1186. DOI |
15 | Peng, W. H., Wu, C. R., Chen, C. S., Chen, C. F., Leu, Z. C. and Hsieh, M. T. 2004. Anxiolytic effect of berberine on exploratory activity of the mouse in two experimental anxiety models: interaction with drugs acting at 5-HT receptors. Life Sci. 75, 2451-2462. DOI |
16 | Prewett, M., Huber, J., Li, Y., Santiago, A., O’Connor, W., King, K., Overholser, J., Hooper, A., Pytowski, B., Witte, L., Bohlen, P. and Hicklin, D. J. 1999. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res. 59, 5209-5218. |
17 | Kitamura, M., Toi, M., Arai, K., Iwasaki, Y., Suzuki, H. and Matsuo, K. 1998. Concentrations of vascular endothelial growth factor in the sera of gastric cancer patients. Oncol. Rep. 5, 1419-1424. |
18 | Kim, J. H., Huh, J. E., Baek, Y. H., Lee, J. D., Choi, D. Y. and Park, D. S. 2011. Effect of Phellodendron amurense in protecting human osteoarthritic cartilage and chondrocytes. J. Ethnopharmacol. 134, 234-242. DOI |
19 | James, M. A., Fu, H., Liu, Y., Chen, D. R. and You, M. 2011. Dietary administration of berberine or Phellodendron amurense extract inhibits cell cycle progression and lung tumorigenesis. Mol. Carcinog. 50, 1-7. DOI |
20 | Kerbel, R. S. 2008. Tumor angiogenesis. N. Engl. J. Med. 358, 2039-2049. DOI |
21 | Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S. and Ferrara, N. 1993. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362, 841-844. DOI |
22 | Ferrara, N. 2001. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am. J. Physiol. Cell Physiol. 280, C1358-C1366. |
23 | Folkman, J. 1974. Proceedings: Tumor angiogenesis factor. Cancer Res. 34, 2109-2113. |
24 | Folkman, J. 1995. Clinical applications of research on angiogenesis. N. Engl. J. Med. 333, 1757-1763. DOI |
25 | Fong, T. A., Shawver, L. K., Sun, L., Tang, C., App, H., Powell, T. J., Kim, Y. H., Schreck, R., Wang, X., Risau, W., Ullrich, A., Hirth, K. P. and McMahon, G. 1999. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 59, 99-106. |
26 | Shaheen, R. M., Davis, D. W., Liu, W., Zebrowski, B. K., Wilson, M. R., Bucana, C. D., McConkey, D. J., McMahon, G. and Ellis, L. M. 1999. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res. 59, 5412-5416. |
27 | Steven, B. 1999. Angiogenesis and cancer control. From concept to therapeutic trial. Cancer Control 5, 436-458. |
28 | Sakurai, Y., Ohgimoto, K., Kataoka, Y., Yoshida, N. and Shibuya, M. 2005. Essential role of flk-1 (VEGF receptor 2) tyrosine residue 1173 in vasculogenesis in mice. Proc. Natl. Acad. Sci. USA 102, 1076-1081. DOI |
29 | Senan, S. and Smit, E. F. 2007. Design of clinical trials of radiation combined with antiangiogenic therapy. Oncologist 12, 465-477. DOI |
30 | Stratmann, J., Wang, C. J., Gnosa, S., Wallin, A., Hinselwood, D., Sun, X. F. and Zhang, H. 2011. Dicer and miRNA in relation to clinicopathological variables in colorectal cancer patients. BMC Cancer 11, 345. DOI |
31 | Lord, S. and Harris, A. L. 2010. Angiogenesis-still a worthwhile target for breast cancer therapy?. Breast Cancer Res. 12 (Suppl. 4), S19. DOI |
32 | Los, M., Roodhart, J. M. and Voest, E. E. 2007. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist 12, 443-450. DOI |
33 | Mori, H., Fuchigami, M., Inoue, N., Nagai, H., Koda, A., Nishioka, I. and Meguro, K. 1995. Principle of the bark Phellodendron amurense to suppress the cellular immune response: effect of Phellodendron on cellular and humoral immune response. Planta. Med. 61, 45-49. DOI |
34 | Ghosh, R., Graham, H., Rivas, P., Tan, X. J., Crosby, K., Bhaskaran, S., Schoolfield, J., Banu, J., Femandes, G., Yeh, I. T. and Kumar, A. P. 2010. Phellodendron amurense bark extract prevents progression of prostate tumors in transgenic adenocarcinoma of mouse prostate: potential for prostate cancer management. Anticancer Res. 30, 857-865. |
35 | Gong, J., Muñoz, A. R., Chan, D., Ghosh, R. and Kumar, A. P. 2014. STAT3 down regulates LC3 to inhibit autophagy and pancreatic cancer cell growth. Oncotarget 15, 2529-2541. |
36 | Galardy, R. E., Grobelny, D., Foellmer, H. G. and Femandez, L. A. 1994. Inhibition of angiogenesis by the matrix metalloprotease inhibitor N-[2R- 2 (hydroxamidocarbonymethyl)-4-methylpentanoyl)]-L-tryptophan methylamide. Cancer Res. 54, 4715-4718. |
37 | Garcia, G. E., Nichole, A., Bhaskaran, S., Gupta, A., Kyprianou, N. and Kumar, A. P. 2006. Akt- and CREB-mediated prostate cancer cell proliferation inhibition by Nexrutine, a Phellodendron amurense extract. Neoplasia 8, 523-533. DOI |
38 | Balbay, M. D., Pettaway, C. A., Kuniyasu, H., Inoue, K., Ramirez, E., Li, E., Fidler, I. J. and Dinney, C. P. 1999. Highly metastatic human prostate cancer growing withinthe prostate of athymic mice overexpresses vascular endothelial growth factor. Clin. Cancer Res. 5, 783-789. |
39 | Brown, K. J., Maynes, S. F., Bezos, A., Maguire, D. J., Ford, M. D. and Parish, C. R. 1996. A novel in vitro assay for human angiogenesis. Lab. Invest. 75, 539-555. |
40 | Carmeliet, P. and Jain, R. K. 2000. Angiogenesis in cancer and other diseases. Nature 407, 249-257. DOI ScienceOn |
41 | Chen, M. L., Lin, Y. H., Yang, C. M. and Hu, M. L. 2012. Lycopene inhibits angiogenesis both in vitro and in vivo by inhibiting MMP-2/uPA system through VEGFR2-mediated PI3K-Akt and ERK/p38 signaling pathways. Mol. Nutr. Food Res. 56, 889-899. DOI |
42 | Nilsson, M. and Heymach, J. V. 2006. Vascular Endothelial Growth Factor (VEGF) pathway. J. Thorac. Oncol. 1, 768-770. DOI |
43 | Oshikawa, J., Kim, S. J., Furuta, E., Caliceti, C., Chen, G. F., Mckinney, R. D., Kuhr, F., Levitan, I., Fukai, T. and Ushio-Fukai, M. 2012. Novel role of p66Shc in ROS-dependent VEGF signaling and angiogenesis in endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 302, H724-H732. DOI |
44 | Moses, M. A. 1997. The regulation of neovascularization by matrix metalloproteinases and their inhibitors. Stem Cells 15, 180-189. DOI |
45 | Muralimanoharan, S. B., Kunnumakkara, A. B., Shylesh, B., Kulkarni, K. H., Haiyan, X., Ming, H., Aggarwal, B. B., Rita, G. and Kumar, A. P. 2009. Butanol fraction containing berberine or related compound from nexrutine inhibits NFkappaB signaling and induces apoptosis in prostate cancer cells. Prostate 69, 494-504. DOI |
46 | Park, E. K., Rhee, H. I., Jung, H. S., Ju, S. M., Lee, Y. A., Lee, S. H., Hong, S. J., Yang, H. I., Yoo, M. C. and Kim, K. S. 2007. Antiinflammatory effects of a combined herbal preparation (RAH13) of Phellodendron amurense and Coptis chinensis in animal models of inflammation. Phytother. Res. 21, 746-750. DOI |
47 | Kumar, A. P., Bhaskaran, S., Ganapathy, M., Crosby, K., Davis, M. D., Kochunov, P., Schoolfield, J., Yeh, I. T., Troyer, D. A. and Ghosh, R. 2007. Akt/cAMP-responsiveelement binding protein/cyclin D1 network: a novel target for prostate cancer inhibition in transgenic adenocarcinoma of mouse prostate model mediated by Nexrutine, a Phellodendron Amurense bark extract. Clin. Cancer Res. 13, 2784-2794. DOI |
48 | Kumar, R., Das, M. and Ansari, K. M. 2012. Nexrutine(R) inhibits tumorigenesis in mouse skin and induces apoptotic cell death in human squamous carcinoma A431 and human melanoma A375 cells. Carcinogenesis 33, 1909-1918. DOI |
49 | Doyle, J. L. and Haas, T. L. 2009. Differential role of beta-catenin in VEGF and histamine-induced MMP-2 production in microvascular endothelial cells. J. Cell. Biochem. 107, 272-283. DOI |
50 | Cho, Y. R., Kim, S. H., Ko, H. Y., Kim, M. D., Choi, S. W. and Seo, D. W. 2011. Sepiapterin inhibits cell proliferation and migration of ovarian cancer cells via down-regulation of p70S6K-dependent VEGFR-2 expression. Oncol. Rep. 26, 861-867. |
51 | Dvorak, H. F. 2002. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 20, 4368-4380. DOI |
52 | Ferrara, N. 2009. Vascular endothelial growth factor. Arterioscler. Thromb. Vasc. Biol. 29, 789-791. DOI |
53 | Ferrara, N. and Henzel, W. J. 1989. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun. 161, 851-858. DOI |